<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215653</url>
  </required_header>
  <id_info>
    <org_study_id>3571-DU-3001</org_study_id>
    <nct_id>NCT04215653</nct_id>
  </id_info>
  <brief_title>A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.</brief_title>
  <official_title>A Phase 3,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole Compared With Rabeprazole in Patients With Duodenal Ulcers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sihuan Pharmaceutical Holdings Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sihuan Pharmaceutical Holdings Group Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3,double-blinded, double dummy, parallel, non-inferiority, randomised controlled
      multicenter trial to evaluate efficacy and safety of 4 weeks treatment of Anaprazole 20mg QD
      compared with rabeprazole 10mg QD in patients with duodenal ulcers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 20, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The endoscopic healing rate of duodenal ulcers at week 4, evaluated by blinded independency central reading.</measure>
    <time_frame>Treatment of 4 weeks</time_frame>
    <description>The endoscopic ulcer healing rate is defined as the percentage of patients healed (complete healing and significant response) in whom the endoscopic response of duodenal ulcers at week 4 has been evaluated by blinded independency central reading.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The endoscopic healing rate of duodenal ulcers at week 4, evaluated by investigator reading.</measure>
    <time_frame>Treatment of 4 weeks</time_frame>
    <description>The endoscopic ulcer healing rate is defined as the percentage of patients healed (complete healing and significant response) in whom the endoscopic response of duodenal ulcers at week 4 has been evaluated by investigators.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">448</enrollment>
  <condition>Duodenal Ulcer，DU</condition>
  <arm_group>
    <arm_group_label>Anaprazole Sodium + Rabeprazole Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administered orally once every 30-60 minutes before breakfast for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rabeprazole +Anaprazole Sodium Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>administered orally once every 30-60 minutes before breakfast for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anaprazole Sodium</intervention_name>
    <description>administered orally once every 30-60 minutes before breakfast for 4 weeks</description>
    <arm_group_label>Anaprazole Sodium + Rabeprazole Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole</intervention_name>
    <description>administered orally once every 30-60 minutes before breakfast for 4 weeks</description>
    <arm_group_label>Rabeprazole +Anaprazole Sodium Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole Placebo</intervention_name>
    <description>administered orally once every 30-60 minutes before breakfast for 4 weeks</description>
    <arm_group_label>Anaprazole Sodium + Rabeprazole Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anaprazole Sodium Placebo</intervention_name>
    <description>administered orally once every 30-60 minutes before breakfast for 4 weeks</description>
    <arm_group_label>Rabeprazole +Anaprazole Sodium Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-70 years, male and female

          2. Has endoscopic diagnosis of active duodenal ulcer(s) (A1 or A2 stage) within 7 days
             prior to randomization

          3. 1 or 2 ulcers, 3-15 mm in diameter.

          4. Signed informed concent form

        Exclusion Criteria:

          1. Has malignancy ulcer or malignancy ulcer not excluded, compouned ulcer, stress ulcer,
             esophageal erosion and ulcer, reflux esophagitis, Zollinger-Ellison syndrome.

          2. Has esophageal and gastric varices；

          3. With severe compliaction, such as pyloric obstruction, bleeding (Forrest I, IIa and
             IIb) or perforation, and etc；

          4. Has gastric ulcer, or has history of inflammatory bowel disease (such as Crohn's
             disease or ulcerative colitis)；

          5. Has undergone surgical resection or partly resection of esophageal, stomach or
             duodenum；

          6. Has used Proton Pump Inhibitors(PPIs) within 5 days prior to randomization, or
             continuous more than 3 days of use of Proton Pump Inhibitors within 2 weeks prior to
             randomization；

          7. Has been treated with triple or quandruple Helicobacter pylori eradication therapy
             included PPIs within 28 days prior to randomization；

          8. Current use the drugs (such as systemic glucocorticoids, non steroid anti-inflammatory
             drugs, or anticoagulation drugs) which may induce ulcer or ulceric bleeding or
             continuous more than 3 days of use the drugs (such as systemic glucocorticoids, non
             steroid anti-inflammatory drugs, or anticoagulation drugs) within 28 days prior to
             randomization；

          9. Laboratory tests performed in screning stage revealed Alanine aminotransferase (ALT)
             or aspartate aminotransferase (AST): &gt; 1.5 upper limit of normal (ULN);

         10. Laboratory tests performed in screning stage revealed thyroid stimulating hormone
             (TSH) or free triiodothyronine (FT3) and free thyroxin ( FT4) : &gt; upper limit of
             normal (ULN)；

         11. Woman in pregnancy or lactation period；

         12. Plan for pregancy or not willing to contracept with reliable contraception method
             during study period and within 90 days after the final time of investigational drug
             administratio；

         13. Have alcohol abuse or drug abuse 1 years prior to screening；

         14. Has hypersensitivity or allergy to investigatory drug, comparatory drug or related
             supplements；

         15. Has participated or been participating other clinical trials(non-interventional study
             is excluded)；

         16. Has an uncotroled disease, such as has a history of significant central nervous system
             (CNS), cardiovascular, pulmonary, hepatic, renal, gastrointestinal, or mental or
             psychological disorders with drug treatment that,in the opinion of the investigator,
             would not be suitable for participating this clinical trial.

         17. Has a history of malignancy or was treated or not treated for malignancy within 5
             years before randomization (the participant may be included in the study if he/she has
             cured cutaneous basal cell carcinoma), no matter if there is evidence for local
             relapse or metastasis；

         18. Laboratory tests performed in screning stage revealed estimated Glomerular filtration
             rate（eGFR） &lt;80 mL/min/1.73 m2 calculated by Modification of Diet in Renal
             Disease(MDRD) equation；

         19. In the opinion of the investigator, the patients with other situation would not be
             suitable for participating this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duodenal Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

